Molecular Templates Inc (MTEM) Return on Equity ROE from the second quarter 2024 to second quarter 2023 and annually, average high and low, overall ranking from Jun 30 2024 to Jun 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Molecular Templates Inc   (NASDAQ: MTEM)

Molecular Templates Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Molecular Templates Inc in the second quarter 2024?
Molecular Templates Inc recorded a cumulative net loss of $-48 million during 12 months ending in the second quarter 2024, resulting in a negative return on equity (ROE) of -807.85%.

Within the Major Pharmaceutical Preparations industry 373 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2024 from 2655 to 3780.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter
Y / Y Equity Change - - - 63.8 % -
Y / Y Net Income Change - -94.73 % - -83.14 % -
Net Income (TTM) in Millions -48 -51 -41 26 47
Return On Equity (TTM) -807.85 % -2497.5 % -38547.76 % - -
MTEM's Total Ranking # 3780 # 2655 # 1 # 0 # 0
Equity (TTM) in Millions 7 6 4 7 -9
Seq. Equity Change 21.14 % 39.36 % -38.07 % - -
Seq. Net Income Change - - - - -

Back to MTEM Management Effectiveness >> MTEM's 5 Years Annual ROE >> Compare MTEM ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 374
Sector # 789
Overall # 3780

Return On Equity Statistics
High Average Low
5414.59 %
349.72 %
-892.77 %
(Dec 31 2023)   (Mar 31 2024)





MTEM Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions 4 -15 66 59 103
Y / Y Equity Change - - 10.65 % -42.4 % 2.1 %
Net Income in Millions 8 93 83 105 69
Y / Y Net Income Change -91.24 % 11.7 % -20.88 % 51.13 % 129.21 %
Return On Equity 192.88 % - 126.42 % 176.8 % 67.38 %

Back to MTEM Management Effectiveness >> MTEM's 5 Years Annual ROE >> Compare MTEM ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2023, company improved ROE to 192.88 % compared to the prior year.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MTEM's' Return on Equity at Yahoo Finance
MTEM's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MTEM's Competitors
Subscribers only: Roe for Molecular Templates Inc 's Suppliers
Subscribers only: Return On Equity for MTEM's Customers




Companies with similar Return On Equity at Jun 30 2024, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.